GlaxoSmithKline Pharmaceuticals Limited (GLAXO) Q2 FY27 Financial Results: PAT ₹25,333 Cr & Revenue ₹92,442 Cr(4 announcements)

GlaxoSmithKline Pharmaceuticals announced management changes effective 3rd August 2026, with Ms. Karine J F Natland appointed as Non-Executive Director and Mr. Bhushan Akshikar reappointed as Managing Director for two years starting 1st December 2026. The company also released unaudited standalone and consolidated financial results for Q1 FY2026, showing revenue of ₹98,605 lakhs and ₹98,220 lakhs respectively, with profit after tax of ₹25,333 lakhs (standalone) and ₹23,718 lakhs (consolidated).

GlaxoSmithKline Pharmaceuticals reported Q1 FY2026 standalone revenue of ₹92,442 lakhs and consolidated revenue of ₹93,844 lakhs, up from ₹80,483 lakhs and ₹80,517 lakhs respectively YoY. Net profit stood at ₹25,333 lakhs standalone and ₹23,718 lakhs consolidated. The Board approved reappointment of Managing Director Bhushan Akshikar for two years effective December 1, 2026, and appointed Karine J F Natland as Non-Executive Director. Subesh Williams resigned from the Board effective close of business on August 3, 2026.

GSK India reported Q1FY27 revenue of INR 924 crores, up 15% YoY, and PAT of INR 253 crores, up 24% YoY, driven by strong performance in General Medicines, Respiratory, Vaccines, and Oncology portfolios. The company highlighted portfolio transformation progress and margin expansion to 32% EBITDA. Key growth drivers included branded products like Augmentin and Nucala, with oncology therapies Jemperli and Zejula gaining market traction. Forward-looking launches include Blenrep and Arexvy, targeting multiple myeloma and RSV respectively.

GlaxoSmithKline Pharmaceuticals reported Q1 FY2027 results for the quarter ended June 30, 2026, showing consolidated revenue of ₹9,822 lakhs and net profit of ₹23,718 lakhs. Standalone revenue was ₹9,860.5 lakhs with net profit of ₹25,333 lakhs. The board approved reappointments of Bhushan Akshikar as Managing Director and Karine J F Natland as Non-Executive Director, while Subesh Williams resigned. The filing includes auditor review confirmation and dividend plans.